Mary Beth Blauwet
- Urology top 0.5%
- Urinary Bladder and Prostate Research 18
- Rheumatology top 2%
- Pelvic floor disorders treatments 9
-
- Cardiac Arrhythmias and Treatments 3
- Atrial Fibrillation Management and Outcomes 3
- Heart Failure Treatment and Management 2
- Cardiac electrophysiology and arrhythmias 2
- Epidemiology top 10%
- Urinary Tract Infections Management 11
-
- Opioid Use Disorder Treatment 2
- Co-authors
- Victor W. ΝittiEmad SiddiquiGary G. KochJ.C. AnguloS. W. ClarkeKirkwood F. AdamsCarla A. SuetaJ. Cambronero
- Partner nations
- United StatesUnited KingdomSpain
In The Last Decade
Mary Beth Blauwet
29 papers receiving 902 citations
Peers
Comparison fields: 5 of 77
- Urology 509
- Rheumatology 415
- Cardiology and Cardiovascular Medicine 299
- Epidemiology 317
- Endocrinology, Diabetes and Metabolism 76
Countries citing papers authored by Mary Beth Blauwet
This map shows the geographic impact of Mary Beth Blauwet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Beth Blauwet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Beth Blauwet more than expected).
Fields of papers citing papers by Mary Beth Blauwet
This network shows the impact of papers produced by Mary Beth Blauwet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Beth Blauwet. The network helps show where Mary Beth Blauwet may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mary Beth Blauwet, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 5 | |
| 2 | 2023 | 1 | |
| 3 | 2023 | 2 | |
| 4 | 2020 | 7 | |
| 5 | 2019 | 27 | |
| 6 | 2015 | 17 | |
| 7 | 2015 | 22 | |
| 8 | 2014 | 22 | |
| 9 | 2014 | 81 | |
| 10 | Post hoc responder analyses of subjective and objective outcomes using pooled data from 3 randomised Phase III trials of mirabegron in patients with overactive bladder | 2013 | 3 |
| 11 | 2013 | 49 | |
| 12 | Age-related efficacy of the selective ß3-adrenoceptor agonist mirabegron for the treatment of overactive bladder (OAB): pooled analysis of three prospective, randomised Phase III studies in patients aged >= 65 years | 2012 | 8 |
| 13 | The Potent and Selective Beta3-adrenoceptor Agonist Mirabegron Improves Patient-reported Outcomes in Overactive Bladder–Results from Two Phase III Studies | 2012 | 1 |
| 14 | Efficacy of mirabegron in patients with overactive bladder (OAB): Pre-specified analysis of three randomised, double-blind, placebo-controlled, Phase III studies | 2012 | 4 |
| 15 | 2011 | 3 | |
| 16 | 1996 | 237 | |
| 17 | 1995 | 10 | |
| 18 | 1994 | 8 | |
| 19 | 1994 | 47 | |
| 20 | 1991 | 21 |
About Mary Beth Blauwet
Mary Beth Blauwet is a scholar working on Urology, Rheumatology and Epidemiology, having authored 31 papers that have together received 933 indexed citations. Recurring topics across this work include Urinary Bladder and Prostate Research (18 papers), Urinary Tract Infections Management (11 papers), Pelvic floor disorders treatments (9 papers), Cardiac Arrhythmias and Treatments (3 papers), Atrial Fibrillation Management and Outcomes (3 papers), Opioid Use Disorder Treatment (2 papers), Heart Failure Treatment and Management (2 papers) and Cardiac electrophysiology and arrhythmias (2 papers). The work is most often cited by research in Urology (509 citations), Rheumatology (415 citations) and Cardiology and Cardiovascular Medicine (299 citations). Mary Beth Blauwet has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Victor W. Νitti, Emad Siddiqui, Gary G. Koch, J.C. Angulo, S. W. Clarke, Kirkwood F. Adams, Carla A. Sueta, J. Cambronero, Nancy Martin and Stephanie H. Dunlap.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.